SANOFI-AVENTIS (EPA:SAN) | Finanzwire

Basculer en Français

9777	Companies
195686	Keywords
126721	Articles
104053	Press releases

Home
Companies
SANOFI-AVENTIS

PRESS RELEASE

published on 08/14/2025 at 07:00, 5 months 16 days ago

Press Release: Sanofi’s rilzabrutinib earns orphan designation in the EU for IgG4-related disease
Sanofi’s rilzabrutinib granted orphan designation in EU for IgG4-related disease. Positive Phase 2 results presented at EULAR 2025 Congress showcasing efficacy and safety profile

Sanofi Rilzabrutinib Orphan Designation IgG4-related Disease EULAR 2025
PRESS RELEASE

published on 08/11/2025 at 18:30, 5 months 19 days ago

Sanofi: Disclosure of trading in own shares
BRIEF

published on 08/06/2025 at 07:05, 5 months 24 days ago

Sanofi Finalizes Acquisition of Vigil Neuroscience

Acquisition Sanofi Neurology Vigil Neuroscience VG-3927
PRESS RELEASE

published on 08/06/2025 at 07:00, 5 months 24 days ago

Press Release: Sanofi completes the acquisition of Vigil Neuroscience, Inc.
Sanofi announces completion of Vigil Neuroscience, Inc. acquisition, reinforcing neurology pipeline with VG-3927 for Alzheimer's. Vigil shareholders receive CVR. VGL101 not acquired

Acquisition Sanofi Neurology Alzheimer's Vigil Neuroscience
BRIEF

published on 07/22/2025 at 07:35, 6 months 8 days ago

Sanofi acquires Vicebio to boost its respiratory vaccine portfolio

Sanofi Acquisition Vicebio Respiratory Vaccines Molecular Clamp Technology Biotechnology Investment
PRESS RELEASE

published on 07/22/2025 at 07:30, 6 months 8 days ago

Press Release: Sanofi to acquire Vicebio, expanding respiratory vaccines pipeline
Sanofi acquires Vicebio, enhancing respiratory vaccines pipeline with 'Molecular Clamp' technology and combination vaccine candidates for RSV and hMPV, expanding capabilities in vaccine development

Sanofi Vicebio Respiratory Vaccines Molecular Clamp Technology Combination Vaccines
BRIEF

published on 07/18/2025 at 07:05, 6 months 12 days ago

Sanofi Completes Acquisition of Blueprint Medicines

Acquisition Sanofi Blueprint Medicines Systemic Mastocytosis Ayvakit
PRESS RELEASE

published on 07/18/2025 at 07:00, 6 months 12 days ago

Press Release: Sanofi completes acquisition of Blueprint Medicines
Sanofi completes acquisition of Blueprint Medicines, adding rare immunology disease medicines to its portfolio. The acquisition includes Ayvakit/Ayvakyt for systemic mastocytosis (SM) and elenestinib for SM, enhancing Sanofi's immunology pipeline

Acquisition Sanofi Immunology Blueprint Medicines Ayvakit/Ayvakyt
BRIEF

published on 07/16/2025 at 07:05, 6 months 14 days ago

Sanofi: Fast track designation for SAR446597 in the United States

FDA Gene Therapy Sanofi Macular Degeneration Fast Track
PRESS RELEASE

published on 07/16/2025 at 07:00, 6 months 14 days ago

Press Release: Sanofi’s SAR446597 earns fast track designation in the US for geographic atrophy due to age-related macular degeneration
Sanofi's SAR446597 receives fast track designation in the US for geographic atrophy due to age-related macular degeneration, aiming to address unmet medical needs with innovative gene therapy

Gene Therapy Sanofi Fast Track Designation Geographic Atrophy SAR446597

Accesswire

Published on 01/30/2026 at 14:00, 7 hours 50 minutes ago

CCL to Hold Live Webcast to Discuss Fourth Quarter and Year End 2025 Results, Thursday, February 26, 2026, at 7:30 a.m. ET
Published on 01/30/2026 at 08:35, 13 hours 15 minutes ago

Alaska Energy Metals Announces Closing Of Life Offering of Units
Published on 01/30/2026 at 08:00, 13 hours 50 minutes ago

Troubadour Resources Intercepts Target Mineralization Near Surface during Phase 1 of the Multi-Phase Drill Program at Senneville Gold-Silver-Copper Property
Published on 01/30/2026 at 02:15, 19 hours 35 minutes ago

Canex Metals Announces Success of Gold Basin Take-Over Bid, Extension of the Partial Revocation of the Cease-Trade Order Imposed on Gold Basin, Waiver of All Remaining Conditions, Initiation of the Share Take Up Process, and Mandatory 10-Day Extension
Published on 01/30/2026 at 00:00, 21 hours 50 minutes ago

LIR Life Sciences Reports Positive Interim Preclinical Results from Comparative Animal Study of Novel CPP-Enabled Transdermal Delivery of GLP/GIP-Based Therapies

View all ACCESSWIRE

EQS Group

Published on 01/30/2026 at 20:10, 1 hour 40 minutes ago

Cynosure Lutronic Announces Completion of EU MDR Approval and Global Momentum for Mosaic 3D™ Ahead of IMCAS 2026
Published on 01/30/2026 at 20:09, 1 hour 41 minutes ago

Aroundtown SA successfully issued AUD 600 million bonds in two tranches
Published on 01/30/2026 at 20:07, 1 hour 43 minutes ago

Aroundtown SA successfully issued AUD 600 million bonds in two tranches
Published on 01/30/2026 at 19:13, 2 hours 37 minutes ago

Total Voting Rights
Published on 01/30/2026 at 18:31, 3 hours 19 minutes ago

Fuller, Smith & Turner PLC: Transaction in own shares

Les Echos

Published on 01/30/2026 at 17:45, 4 hours 5 minutes ago

Schneider Electric launches a capital increase reserved for employees
Published on 01/30/2026 at 08:00, 13 hours 50 minutes ago

AMA: 4th Quarter & FY 2025 Revenues
Published on 01/29/2026 at 18:00, 1 day 3 hours ago

GUILLEMOT CORPORATION: FULL-YEAR 2025 CONSOLIDATED TURNOVER UP 2%
Published on 01/29/2026 at 17:45, 1 day 4 hours ago

LANSON-BCC ANNOUNCES 2025 REVENUES AND FINALISES THE ACQUISITION OF HEIDSIECK & C° MONOPOLE
Published on 01/29/2026 at 17:45, 1 day 4 hours ago

Cegedim generated LFL revenue growth of 1.1% in 2025

View all LES ECHOS COMFI WIRE